Cancer Risk Higher for Men Versus Women at Most Shared Anatomic Sites
The proportion of excess cancer risk in men that was explained by risk factors was modest, ranging from 50 to 11%
Diagnosis & Disease Information
Opioid Use in Advanced Urothelial Carcinoma Quantified
Pain requiring opioids is more common among patients with locally advanced or metastatic urothelial carcinoma compared with a matched control group of patients without cancer, a study found.
Risk Stratification Examined for High-Grade Ta Bladder Tumors
For patients treated with adequate BCG, risk for BCG unresponsiveness, progression similar for all high-grade Ta tumors
Recurrent NMIBC Effectively Treated With Salvage Valrubicin+Docetaxel
Investigators studied the effect of sequential valrubicin and docetaxel in patients with recurrent NMIBC following treatment with intravesical bacillus Calmette-Guérin and/or gemcitabine-docetaxel.
Prostate Cancer Radiation Therapy Ups Risks for a Second Cancer
Although the risks of developing a second primary cancer after radiation therapy were relatively small, they increased over time.
Olaparib Does Not Improve Outcomes in Platinum-Ineligible Metastatic Urothelial Carcinoma
Adding olaparib to durvalumab did not improve progression-free or overall survival.
Data Support Trimodal Therapy for Muscle-Invasive Bladder Cancer
A propensity-score matched comparison revealed no significant difference in oncologic outcomes between radical cystectomy and trimodal therapy.
Anemia Ups Risk for Radical Cystectomy Complications
Anemia can identify patients at higher risk for radical cystectomy complications and may be useful in preoperative counseling, according to investigators.
Second Primary Cancers Less Likely With IMRT vs CRT for Prostate Tumors
Among patients receiving radiation therapy (RT) for prostate cancer, intensity-modulated radiation therapy is significantly associated with a reduced risk for second primary solid malignancies compared with 3D conformal RT.
Tislelizumab Shows Promise for High-Risk Nonmuscle-Invasive Bladder Cancer
Investigators observed a complete response in more than half of patients treated with tislelizumab plus nab-paclitaxel for high-risk NMIBC that was not completely resectable.
- Loading...
Loading...
Next post in Bladder Cancer
Loading... 
Loading...